Setting 
My Cart
Toggle Nav
mobile icon
Close
  • Menu
  • Setting

Protein Tyrosine Kinase/RTK

Items 111-120 of 128

Page
per page
  1. BIBF 1202
    A4694 BIBF 1202
    Summary: A VEGFR2 kinase inhibitor for tumor angiogenesis mechanisms
      ≥54.9 mg/mL
  2. Zanubrutinib
    A4693 Zanubrutinib
    Summary: A BTK inhibitor for the treatment of mantle cell lymphoma and other B-cell malignancies
      ≥52.1 mg/mL
  3. Gilteritinib
    A4691 Gilteritinib
    Summary: A FLT3 kinase inhibitor for the treatment of acute myeloid leukemia
      ≥5.68 mg/mL
  4. Pemigatinib
    A4690 Pemigatinib
    Summary: An orally selective FGFR inhibitor for the treatment of cholangiocarcinoma
      ≥49.9 mg/mL
  5. Pexidartinib hydrochloride
    A4687 Pexidartinib hydrochloride
    Summary: An orally administered potent ATP-competitive CSF1R and c-Kit kinase inhibitor
      ≥49 mg/mL
  6. Larotrectinib
    A4684 Larotrectinib
    Summary: An orally administered selective TRK-inhibiting antitumor agent
      ≥51.2 mg/mL
  7. Zipalertinib
    A4683 Zipalertinib
    Summary: An oral kinase inhibitor that selectively targets the ATP-binding site in the EGFR hinge region
      ≥23.85 mg/mL
  8. Defactinib hydrochloride
    A4651 Defactinib hydrochloride
    Summary: A dose- and time-dependent inhibitor of FAK Tyr397 phosphorylation
      ≥15.75 mg/mL
  9. Repotrectinib
    A4650 Repotrectinib
    Summary: A tyrosine kinase inhibitor for the treatment of ROS1-positive non-small cell lung cancer
      ≥17 mg/mL
  10. Alectinib Hydrochloride
    A4649 Alectinib Hydrochloride
    Summary: A highly selective, orally available ALK inhibitor with central nervous system penetration
      ≥6.89 mg/mL

Items 111-120 of 128

Page
per page
Relate Categories
Category
  1. FGFR3item